Comments
Roche Products (India) and Cipla Ltd have entered into an agreement to improve access to innovative medicines for patients in India, the companies said.
Under the agreement, Cipla will be responsible for marketing and distribution of Roche Pharma’s key trademark oncology drugs Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova).
Roche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products.
V Simpson Emmanuel, General Manager, Roche Products (India), said, “This deal will ensure that our focus on providing Roche innovations in India remains steadfast in this portfolio and we will keep on collaborating with the relevant stakeholders in the Indian healthcare system to ensure better outcomes for patient.”
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.